the bio screening core facility
play

The Bio-Screening Core Facility PETER BANKS PETER.BANKS@NCL.AC.UK - PowerPoint PPT Presentation

The Bio-Screening Core Facility PETER BANKS PETER.BANKS@NCL.AC.UK CARMEN MARTIN-RUIZ CARMEN.MARTIN-RUIZ@NCL.AC.UK Bio-Screening Facility Information High Throughput Screening Facility Biomarker Facility Peter Banks Carmen Martin-Ruiz


  1. The Bio-Screening Core Facility PETER BANKS PETER.BANKS@NCL.AC.UK CARMEN MARTIN-RUIZ CARMEN.MARTIN-RUIZ@NCL.AC.UK

  2. Bio-Screening Facility Information High Throughput Screening Facility Biomarker Facility Peter Banks Carmen Martin-Ruiz Peter.Banks@ncl.ac.uk Carmen.Martin-Ruiz@ncl.ac.uk Claire Kolenda Claire.Kolenda@ncl.ac.uk Craig Parker Craig.Parker@ncl.ac.uk Cookson/Leech Building Ageing Research Labs Medical School Campus for Ageing and Vitality https://www.ncl.ac.uk/htsf/ https://www.ncl.ac.uk/ion/about/facilities/biomarkers/

  3. High Throughput Screening Combine robotics, high throughput reagents and expertise to provide a bespoke cell based screening service to all researchers in FMS ◦ Laboratory Automation ◦ Genetic screening services for a range of organisms ◦ Drug screening in collaboration with LifeArc

  4. Equipment 2 sites – 2 nd floor Cookson and 2 nd floor Leech Liquid handling mammalian cells ◦ Beckman FX within a sterile enclosure – Class II ◦ Beckman FX – Class I Colony Pinning microbes ◦ S&P BM3 ◦ S&P BM5 ◦ Singer ROTOR Data collection ◦ Agar plate imaging systems ◦ Automated plate readers ◦ High Content Imaging system – Bioimaging ◦ High Throughput Flow Cytometer – FACS Ancillary ◦ Agar plate pouring ◦ Multi well plate filling

  5. Genetic Screening Cell based genetic screening is the combination of Yeast collections laboratory automation with high throughput ◦ Deletion library ~4500 strains biological reagents. ◦ Overexpression library ~6000 strains ◦ Identify new research directions ◦ DaMP Library ~800 strains ◦ Preliminary data generation for grant applications ◦ Histone point mutant library ~ 400 strains ◦ Temperature sensitive collections Bacterial collections High throughput reagents are specifically designed ◦ Bacillus subtilis for automation ◦ Escherichia coli ◦ Excellent coverage for large scale experiments ◦ Post screen validation is critical to success Dharmacon Human siRNA library

  6. Dharmacon siRNA Library ◦ G Protein Coupled Receptors Dharmacon siGENOME SMARTpool siRNA library ◦ Protein Kinases -3 plates ◦ siGENOME – type of siRNA ◦ Ion Channels ◦ 4 siRNAs to a single gene in one well – SMARTpool ◦ Phosphatases – 1 plate ◦ ~7500 genes over 28 plates ◦ Proteases ◦ 1nmol in four separate 384 well plates ◦ Ubiquitin Conjugation 1 - Cullins, E1, E2, HECT E3 ◦ Screen 400-2000 plates Ligases ◦ Supply the gene list ◦ Ubiquitin Conjugation 2 - F-box, SOCS box E3 Ligases ◦ Add individual controls to experiments ◦ Ubiquitin Conjugation 3 - RING finger and RING finger-like E3 Ligases ◦ Drug Targets Cherry pick individual 384 or 96 well plates

  7. Drug Screening The HTSF has a collaboration with the life science Index library charity LifeArc to provide FMS researchers with ◦ ~12,000 compounds representative of full LifeArc collection drug screening ◦ LifeArc links basic research to industrial collaborators Kinase library ◦ Expertise – medicinal chemistry, IP and screening ◦ ~6,700 compounds predicted to inhibit kinases ◦ Provided a 20,000 compound library to screen here Natural product library Free to access the libraries ◦ ~1000 purified novel natural products from plants or ◦ LifeArc need to approve the screen fungi Libraries supplied blind FDA approved drugs library ◦ Results must be fed back to LifeArc to deconvolute ◦ ~1,000 compounds 20ul of drug at 10mM in DMSO ◦ 50-200 plates

  8. Case Study – Candida Virulence Developed a high throughput assay for virulence factors ◦ Natural product library ◦ FDA approved drugs library ◦ Preliminary data for a BBSRC grant Screened the 20000 compound LifeArc collection ◦ Initial hit list of ~200 compounds ◦ Many related compounds ◦ Up to 2000 analog compounds

  9. Biomarkers Biomarker: a (molecular) characteristic objectively measured and evaluated as an indicator of normal or pathogenic biological processes An experienced laboratory offering a wide range of procedures to process ◦ Clinical: GCP, GCLP, SOPs, BioCOSHH, HTA ◦ Non-clinical research samples: cell cultures, bird, monkeys, mice, rat... Expertise on the screening of candidate biomarkers Intermediate and flexible capability. “Mid-throughput” Epidemiological value on actual samples

  10. Sample Handling & Technical Support Blood processing and blood cell separation Sampling logistics ◦ PBMC isolation, buffy coats, ◦ Optimal use of blood samples. ◦ PAXgene tubes ◦ Suitability of anticoagulant (or not!) ◦ Cell Preparation Tubes (CPT) ◦ Phlebotomy requirements: blood volumes, timings, priorities ◦ Red cells conditioning Sample tracking Plasma and Serum ◦ Labelling and Barcoding ◦ Pre-treatment and conditioning (anti-oxidants) ◦ Achiever compatible datasets ◦ Aliquoting Coordination with Clinical/Research Teams ◦ RVI/Freeman Labs and CARU ◦ Nationwide and overseas

  11. Follow-up Sample Processing DNA Isolation RNA Isolation ◦ Phenol/Chloroform or Spin columns ◦ PAXgene tubes ◦ Blood samples ◦ Fresh bloods ◦ Tissues ◦ Cell pellets ◦ Cell pellets ◦ Saliva swabs Specialized processing ◦ Blood spot cards ◦ Cryogenic conditioning of cells, cryopreservation ◦ Feathers ◦ Cell culture ◦ Nails ◦ Cytokines: LPS-stimulation, blood cultures DNA & RNA isolation ◦ Flow cytometry ◦ From same sample .... and more ◦ Fresh bloods, tissue ◦ Cell pellets

  12. Biomarker Analysis RNA and Gene expression analysis Novel biomarkers: ◦ RT-qPCR, 384-well capacity, ◦ From cell culture to humans ◦ TaqMan Gene expression assays, ◦ TaqMan MicroRNA assays Novel sources of material: ◦ From humans to animals DNA and Genotyping ◦ Genotyping by Agarose Gels (Mice Ear Notches) Epidemiological scaling: ◦ Genotyping by qPCR (inc.TaqMan™ Genotyping) ◦ From single sample to 384-well plates ◦ Telomeres, ApoE, SNPs ◦ E.g Telomeres DNA damage and repair analysis Methodological validation: Protein assays ◦ Detection limits ◦ Serum/plasma/blood cells/culture supernatants ◦ Coefficients of variation ◦ Sandwich ELISA, Competitive ELISA ◦ Dilutions ◦ 96-well and 384-well plates ◦ Sensitivity ◦ Oxidative Damage ◦ Enzymatic activity (e.g. telomerase)

  13. In-house Measurements ◦ Handling of complex sample logistics, regulatory frameworks ◦ Rational use of samples, maximum potential ◦ Large collections: traceability and timely delivery of results ◦ Beyond routine Clinical Biochemistry – added value ◦ “Made to measure”- with you through the whole process ◦ Explore new methodologies ◦ Detailed costing

  14. Case Study 1 – StemBANCC StemBANCC 5 year programme (EU 7th FP) CARU team part of the multi-centre recruiting process with blood samples requiring a standardized processing for biobanking by a third party. Biomarkers lab ◦ Coordinating with Biobank lab ◦ Coordinating with CARU nurses ◦ On the day CARU nurse assesses participant, collect blood and within 5min the sample is at Biomarkers lab for • Sample processing • Cryopreservation • Safe storage and final shipping to Biobank

  15. Case Study 2 – Starlings Biomarker lab previous work in humans: potential to translate onto birds Telomeres ◦ Develop and improve a previous method on bird telomeres ◦ Isolate DNA and assess telomeres at large scale (N~600) Inflammatory markers in birds ◦ Develop and validate method for IL-6 and hsCRP in birds with very limited amount of plasma. ◦ Measure IL-6 and hsCRP on same sample (N>120 samples) ◦ Final publication: from writing up methods to replies to reviewers Genotyping for sexing of birds ◦ Test 3 previous methods on genomic sexing of these birds ◦ Evaluate gender on large collection of samples (N~400)

  16. Case Study 3 - Pre-eclampsia RVI Biomarker lab previous work on inflammatory markers: Apply those biomarkers and develop new ones (Myeloperoxidase, MPO) in Pre-eclampsia. ◦ Assess IL-6 and TNA-alpha in plasma samples (N=190) ◦ Test 3 possible samples for measurement of Myeloperoxidase ◦ Develop, up-scale and increase sensitivity of current MPO assay ◦ Higher throughput and Higher reproducibility

  17. General Support Ad hoc technical support ◦ When you needed, where you needed Support with Costings and Grant applications ◦ Flexible detailed costings ◦ Co-applicants or service providers Post-graduate training and support Writing up: Methods, reviewers reply, etc.

  18. For further details, please contact: Dr Carmen Martin-Ruiz Biomarkers Lab Manager Campus for Ageing and Vitality Newcastle upon Tyne, NE4 5PL Tel: +44(0)191 2081107 E-mail: carmen.martin-ruiz@ncl.ac.uk http://www.ncl.ac.uk/ion/about/facilities/biomarkers/

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend